+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Rare Inflammatory Disease Treatment Market by Therapeutic Class (Biologics, Cell Therapy, Gene Therapy), Mechanism of Action (B-Cell Depleting Agents, Il Inhibitors, Jak Inhibitors), Route of Administration, Distribution Channel, End User - Global Forecast 2025-2030- Product Image
Rare Inflammatory Disease Treatment Market by Therapeutic Class (Biologics, Cell Therapy, Gene Therapy), Mechanism of Action (B-Cell Depleting Agents, Il Inhibitors, Jak Inhibitors), Route of Administration, Distribution Channel, End User - Global Forecast 2025-2030- Product Image
Sale

Rare Inflammatory Disease Treatment Market by Therapeutic Class (Biologics, Cell Therapy, Gene Therapy), Mechanism of Action (B-Cell Depleting Agents, Il Inhibitors, Jak Inhibitors), Route of Administration, Distribution Channel, End User - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 191 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6120813
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The landscape of rare inflammatory diseases presents both formidable challenges and unprecedented opportunities for stakeholders across research, clinical development, and commercial arenas. This executive summary is designed to orient decision makers and thought leaders to the critical dynamics influencing innovation in this field. It distills complex data into clear insights that support strategic planning, investment prioritization, and collaborative endeavors aimed at enhancing patient outcomes.

By outlining the scope of this analysis, including key thematic areas and methodological approaches, the introduction establishes a structured framework for the subsequent sections. Readers will gain a concise overview of the report’s objectives, its relevance to emerging therapeutic modalities, and its utility in addressing regulatory, reimbursement, and market access considerations. Ultimately, it sets the stage for an in-depth exploration of transformative shifts, segmentation nuances, regional variances, and recommendations that collectively inform a roadmap for advancing rare inflammatory disease therapies.

Exploring the Most Significant Transformative Shifts Reshaping the Treatment Landscape for Rare Inflammatory Diseases in Recent Years and Emerging Trends Impacting Future Therapeutic Development and Patient Care Strategies

Over the past decade, the rare inflammatory disease landscape has been reshaped by groundbreaking advances in molecular science and evolving patient care paradigms. The emergence of targeted biologics, including monoclonal antibodies and fusion proteins, has fundamentally altered treatment protocols, enabling precision modulation of immune pathways previously untreatable with conventional small molecules. These innovations have set a new benchmark for efficacy and safety, driving faster regulatory approvals and broader patient access programs.

Concurrently, the development of cell and gene therapies has introduced the promise of durable remission and potential cures. Early successes in autologous cell therapies have catalyzed investment in allogeneic platforms, while gene editing technologies offer the prospect of lifelong correction of underlying genetic drivers. These shifts are complemented by digital health solutions that enhance remote monitoring and patient adherence, integrating real-world evidence into clinical decision making. As a result, stakeholders must navigate an increasingly complex ecosystem, balancing disruptive therapeutic options with evolving payer expectations and infrastructure demands to ensure that innovation translates into tangible benefit for patients with rare inflammatory conditions.

Assessing the Cumulative Impact of United States Tariff Changes in 2025 on the Rare Inflammatory Disease Therapeutics Market and Supply Chain Dynamics

In 2025, the introduction of revised tariff schedules in the United States has had a pronounced cumulative effect on the supply chain economics of rare inflammatory disease therapeutics. Adjusted levies on active pharmaceutical ingredients and key biologic components have elevated production costs, prompting manufacturers to reassess sourcing strategies and consider rebalancing global manufacturing footprints. These adjustments have reverberated through contract negotiations with wholesalers and distributors, necessitating more nuanced pricing models to preserve margin integrity.

Moreover, the heightened cost of imported excipients and ancillary materials has spurred innovation in local vendor partnerships, as companies seek to mitigate tariff exposure and reduce lead times. Regulatory agencies and industry consortia are also engaging in dialogue to streamline customs processes for critical therapies, recognizing patient access imperatives. As a result, organizations are adopting scenario planning frameworks to evaluate the interplay between trade policy shifts, cost-to-serve implications, and long-term supply continuity. These proactive measures lay the groundwork for resilient supply chain configurations and adaptive pricing strategies amid an increasingly fluid trade environment.

Deriving Key Segmentation Insights from Therapeutic Class Mechanism Route and Distribution Channel Analyses to Inform Targeted Development for Rare Inflammatory Diseases

A comprehensive segmentation analysis reveals critical insights into how varying therapeutic classes, mechanisms of action, routes of administration, distribution channels, and end user settings converge to shape development priorities in rare inflammatory diseases. By examining biologics across fusion proteins and monoclonal antibodies-each further distinguished by B-cell depleting agents, interleukin inhibitors, and tumor necrosis factor inhibitors-makers can identify high-value targets and competitive white spaces. Within mechanistic categories such as anti-CD19 versus anti-CD20 approaches, and JAK isoform-specific inhibitors, subtle efficacy and safety differentials drive tailored pipeline strategies.

Administration routes ranging from intravenous infusions to oral regimens and topical formulations influence patient convenience and adherence, guiding formulation development. Channels spanning hospital, retail, and specialty pharmacies dictate distribution logistics and reimbursement protocols, while the growing role of home care settings, hospitals, and specialty clinics highlights the importance of patient support integration and caregiver training. Taken together, these segmentation insights enable a holistic perspective that aligns R&D investment with market access pathways, ensuring that emerging therapies meet nuanced clinical and commercial criteria across the rare inflammatory disease spectrum.

Highlighting Key Regional Insights Across Americas EMEA and Asia Pacific to Illuminate Geographic Variations in Rare Inflammatory Disease Treatment Adoption and Access

Geographic considerations profoundly influence the adoption, access, and evolution of rare inflammatory disease treatments. In the Americas, robust research infrastructure, combined with streamlined regulatory mechanisms, has facilitated rapid approvals of novel biologics and cell therapies. However, disparities in insurance coverage and variable state-level formularies require adaptive market access strategies that balance patient assistance programs with pricing negotiations.

Across Europe, the Middle East & Africa, collaborative frameworks between health authorities and industry have enabled joint tendering processes and cross-border reimbursement agreements, improving patient reach in smaller markets. However, the complexity of multi-country regulatory alignments and differing health technology assessment criteria necessitate comprehensive value dossiers and real-world evidence generation to support pricing and reimbursement. Meanwhile, the Asia-Pacific region exhibits a dynamic convergence of emerging economies investing heavily in domestic manufacturing and innovative public-private partnerships to localize supply chains. As regulatory harmonization progresses and digital health adoption accelerates, regional stakeholders are positioned to integrate advanced therapies more efficiently, underscoring the importance of tailored market entry and stakeholder engagement strategies in each territory.

Uncovering Strategic Insights into Leading Companies Driving Innovation and Competitive Dynamics in the Rare Inflammatory Disease Therapeutics Market

Leading companies in the rare inflammatory disease arena are consolidating their competitive advantage through differentiated pipelines, strategic collaborations, and targeted acquisitions. Established pharmaceutical leaders are expanding their biologics portfolios by integrating next-generation monoclonal antibodies with enhanced specificity for interleukin subtypes, while pioneering gene therapy developers are advancing in vivo delivery platforms that promise sustained remission.

At the same time, agile biotech firms are forging alliances with advanced analytics providers to leverage real-world patient data in optimizing trial design and accelerating regulatory submissions. Several organizations are also teaming with contract development and manufacturing organizations to scale cell therapy production, ensuring consistent quality and supply. The competitive landscape is further defined by concerted efforts to build patient-centric ecosystems, embedding digital health tools that facilitate remote monitoring, adherence support, and outcome tracking. Collectively, these strategic initiatives underscore how industry leaders are orchestrating scientific innovation, manufacturing excellence, and patient engagement to maintain momentum in this rapidly evolving market.

Providing Actionable Recommendations for Industry Leaders to Accelerate Therapeutic Innovation Regulatory Strategy and Market Entry in Rare Inflammatory Diseases

Industry leaders can capitalize on emerging opportunities by prioritizing strategic investment in advanced biologic modalities while simultaneously de-risking asset portfolios through diversified mechanism-of-action approaches. Early and continuous engagement with regulatory bodies is essential to define accelerated pathways for novel therapies, particularly in cell and gene domains. Furthermore, forging strategic partnerships with specialized contract manufacturers can ensure scalable and cost-efficient production while maintaining rigorous quality standards.

Integrating real-world evidence platforms into clinical development programs will bolster value propositions and strengthen reimbursement dialogues. Equally important is the cultivation of robust patient support networks that enhance adherence and gather longitudinal outcome metrics. Companies should also explore modular supply chain architectures that facilitate regional customization in response to tariff fluctuations and distribution channel nuances. By aligning R&D pipelines with precise segmentation insights and regional market dynamics, organizations can achieve sustainable competitive differentiation and deliver transformative therapies to underserved patient populations.

Outlining a Robust Research Methodology Incorporating Primary Secondary Data Triangulation Expert Interviews and Rigorous Analytical Frameworks for Market Insights

This report’s findings are anchored in a rigorous research methodology that integrates primary data collection, secondary literature review, and advanced analytical models. Interviews with leading clinicians, industry executives, and payers provided qualitative perspectives on therapeutic performance, regulatory trends, and market access barriers. Comprehensive review of peer-reviewed journals, clinical trial registries, and regulatory disclosures ensured the incorporation of the latest scientific evidence.

Quantitative analysis leveraged proprietary databases to examine development pipelines, patent portfolios, and manufacturing capacities. Segment-level triangulation validated market dynamics across therapeutic classes, mechanisms, and geographies. Scenario planning and sensitivity analyses were conducted to assess the impact of tariff changes and policy shifts on cost structures. Peer validation workshops engaged external experts to challenge assumptions and refine insights. This multifaceted approach ensures that the report delivers robust, actionable intelligence, tailored to inform strategic decision making in the rare inflammatory disease domain.

Concluding Insights Summarizing Critical Findings Transformative Shifts and Strategic Imperatives for Advancing Rare Inflammatory Disease Treatments Globally

In conclusion, the rare inflammatory disease treatment landscape is at a pivotal juncture defined by scientific breakthroughs, evolving trade policies, and intricate market dynamics. Transformative shifts in biologics, cell and gene therapies have set new standards for efficacy, while the ramifications of 2025 tariff revisions necessitate agile supply chain strategies. Segmentation analyses underscore the importance of nuanced insights across therapeutic classes, mechanisms of action, administration routes, distribution channels, and end user settings.

Regional variances in the Americas, Europe, Middle East & Africa, and Asia-Pacific further highlight the need for tailored market entry and access frameworks. Leading companies are differentiating through strategic collaborations, pipeline diversification, and patient-centric solutions. By implementing targeted recommendations such as early regulatory engagement, diversified modality investment, and supply chain modularization, industry stakeholders can navigate complexity and advance therapeutic innovations. This executive summary equips decision makers with the foundational knowledge required to drive impactful progress in rare inflammatory disease research, development, and commercialization.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Therapeutic Class
    • Biologics
      • Fusion Proteins
      • Monoclonal Antibodies
        • B-Cell Depleting Agents
        • Il Inhibitors
          • Il-1 Inhibitors
          • Il-17 Inhibitors
          • Il-6 Inhibitors
        • Tnf Inhibitors
    • Cell Therapy
    • Gene Therapy
    • Small Molecules
      • Jak Inhibitors
      • Pde4 Inhibitors
      • Syk Inhibitors
  • Mechanism Of Action
    • B-Cell Depleting Agents
      • Anti-Cd19
      • Anti-Cd20
    • Il Inhibitors
      • Il-1 Inhibitors
      • Il-17 Inhibitors
      • Il-6 Inhibitors
    • Jak Inhibitors
      • Jak1
      • Jak2
      • Jak3
    • Tnf Inhibitors
  • Route Of Administration
    • Intravenous
    • Oral
    • Subcutaneous
    • Topical
  • Distribution Channel
    • Hospital Pharmacy
    • Retail Pharmacy
    • Specialty Pharmacy
  • End User
    • Home Care Settings
    • Hospitals
    • Specialty Clinics
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report delves into recent significant developments and analyzes trends in each of the following companies:
  • F. Hoffmann-La Roche AG
  • Novartis AG
  • Johnson & Johnson
  • Sanofi S.A.
  • Pfizer Inc.
  • AbbVie Inc.
  • Takeda Pharmaceutical Company Limited
  • AstraZeneca PLC
  • Amgen Inc.
  • Bristol-Myers Squibb Company

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Patient-centric digital biomarkers transforming disease monitoring and trial design for rare inflammatory conditions
5.2. Emergence of bispecific antibodies targeting multiple inflammatory pathways for refractory rare autoimmune disorders
5.3. Adoption of gene editing therapies to achieve durable remission in genetically driven rare inflammatory diseases
5.4. Utilization of real-world evidence and decentralized clinical trials to accelerate rare disease treatment approvals
5.5. Strategic collaborations between biotech startups and established pharma to advance novel precision therapies for rare inflammation
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Rare Inflammatory Disease Treatment Market, by Therapeutic Class
8.1. Introduction
8.2. Biologics
8.2.1. Fusion Proteins
8.2.2. Monoclonal Antibodies
8.2.2.1. B-Cell Depleting Agents
8.2.2.2. Il Inhibitors
8.2.2.2.1. Il-1 Inhibitors
8.2.2.2.2. Il-17 Inhibitors
8.2.2.2.3. Il-6 Inhibitors
8.2.2.3. Tnf Inhibitors
8.3. Cell Therapy
8.4. Gene Therapy
8.5. Small Molecules
8.5.1. Jak Inhibitors
8.5.2. Pde4 Inhibitors
8.5.3. Syk Inhibitors
9. Rare Inflammatory Disease Treatment Market, by Mechanism of Action
9.1. Introduction
9.2. B-Cell Depleting Agents
9.2.1. Anti-Cd19
9.2.2. Anti-Cd20
9.3. Il Inhibitors
9.3.1. Il-1 Inhibitors
9.3.2. Il-17 Inhibitors
9.3.3. Il-6 Inhibitors
9.4. Jak Inhibitors
9.4.1. Jak1
9.4.2. Jak2
9.4.3. Jak3
9.5. Tnf Inhibitors
10. Rare Inflammatory Disease Treatment Market, by Route of Administration
10.1. Introduction
10.2. Intravenous
10.3. Oral
10.4. Subcutaneous
10.5. Topical
11. Rare Inflammatory Disease Treatment Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacy
11.3. Retail Pharmacy
11.4. Specialty Pharmacy
12. Rare Inflammatory Disease Treatment Market, by End User
12.1. Introduction
12.2. Home Care Settings
12.3. Hospitals
12.4. Specialty Clinics
13. Americas Rare Inflammatory Disease Treatment Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Rare Inflammatory Disease Treatment Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Rare Inflammatory Disease Treatment Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. F. Hoffmann-La Roche AG
16.3.2. Novartis AG
16.3.3. Johnson & Johnson
16.3.4. Sanofi S.A.
16.3.5. Pfizer Inc.
16.3.6. AbbVie Inc.
16.3.7. Takeda Pharmaceutical Company Limited
16.3.8. AstraZeneca PLC
16.3.9. Amgen Inc.
16.3.10. Bristol-Myers Squibb Company
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. RARE INFLAMMATORY DISEASE TREATMENT MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2024 VS 2030 (%)
FIGURE 6. GLOBAL RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 12. GLOBAL RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. RARE INFLAMMATORY DISEASE TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. RARE INFLAMMATORY DISEASE TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 25. RARE INFLAMMATORY DISEASE TREATMENT MARKET: RESEARCHAI
FIGURE 26. RARE INFLAMMATORY DISEASE TREATMENT MARKET: RESEARCHSTATISTICS
FIGURE 27. RARE INFLAMMATORY DISEASE TREATMENT MARKET: RESEARCHCONTACTS
FIGURE 28. RARE INFLAMMATORY DISEASE TREATMENT MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. RARE INFLAMMATORY DISEASE TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY FUSION PROTEINS, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY FUSION PROTEINS, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY B-CELL DEPLETING AGENTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY B-CELL DEPLETING AGENTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY IL INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY IL INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY IL-1 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY IL-1 INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY IL-17 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY IL-17 INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY IL-6 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY IL-6 INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY IL INHIBITORS, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY IL INHIBITORS, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY TNF INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY TNF INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY CELL THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY CELL THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY GENE THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY JAK INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY JAK INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY PDE4 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY PDE4 INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY SYK INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY SYK INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY SMALL MOLECULES, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY SMALL MOLECULES, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY B-CELL DEPLETING AGENTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY B-CELL DEPLETING AGENTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY ANTI-CD19, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY ANTI-CD19, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY ANTI-CD20, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY ANTI-CD20, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY B-CELL DEPLETING AGENTS, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY B-CELL DEPLETING AGENTS, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY IL INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY IL INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY IL-1 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY IL-1 INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY IL-17 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY IL-17 INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY IL-6 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY IL-6 INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY IL INHIBITORS, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY IL INHIBITORS, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY JAK INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY JAK INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY JAK1, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY JAK1, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY JAK2, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY JAK2, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY JAK3, BY REGION, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY JAK3, BY REGION, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY JAK INHIBITORS, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY JAK INHIBITORS, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY TNF INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY TNF INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 85. GLOBAL RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 87. GLOBAL RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 88. GLOBAL RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 89. GLOBAL RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY TOPICAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 90. GLOBAL RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY TOPICAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 91. GLOBAL RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 92. GLOBAL RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 93. GLOBAL RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 94. GLOBAL RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 95. GLOBAL RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 96. GLOBAL RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 97. GLOBAL RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY SPECIALTY PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 98. GLOBAL RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY SPECIALTY PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 99. GLOBAL RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 100. GLOBAL RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 101. GLOBAL RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
TABLE 102. GLOBAL RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2025-2030 (USD MILLION)
TABLE 103. GLOBAL RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 104. GLOBAL RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 105. GLOBAL RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 106. GLOBAL RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 107. AMERICAS RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
TABLE 108. AMERICAS RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2030 (USD MILLION)
TABLE 109. AMERICAS RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
TABLE 110. AMERICAS RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
TABLE 111. AMERICAS RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 112. AMERICAS RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 113. AMERICAS RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY IL INHIBITORS, 2018-2024 (USD MILLION)
TABLE 114. AMERICAS RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY IL INHIBITORS, 2025-2030 (USD MILLION)
TABLE 115. AMERICAS RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY SMALL MOLECULES, 2018-2024 (USD MILLION)
TABLE 116. AMERICAS RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY SMALL MOLECULES, 2025-2030 (USD MILLION)
TABLE 117. AMERICAS RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 118. AMERICAS RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 119. AMERICAS RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY B-CELL DEPLETING AGENTS, 2018-2024 (USD MILLION)
TABLE 120. AMERICAS RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY B-CELL DEPLETING AGENTS, 2025-2030 (USD MILLION)
TABLE 121. AMERICAS RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY IL INHIBITORS, 2018-2024 (USD MILLION)
TABLE 122. AMERICAS RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY IL INHIBITORS, 2025-2030 (USD MILLION)
TABLE 123. AMERICAS RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY JAK INHIBITORS, 2018-2024 (USD MILLION)
TABLE 124. AMERICAS RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY JAK INHIBITORS, 2025-2030 (USD MILLION)
TABLE 125. AMERICAS RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 126. AMERICAS RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 127. AMERICAS RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 128. AMERICAS RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 129. AMERICAS RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 130. AMERICAS RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 131. AMERICAS RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 132. AMERICAS RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 133. UNITED STATES RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
TABLE 134. UNITED STATES RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2030 (USD MILLION)
TABLE 135. UNITED STATES RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
TABLE 136. UNITED STATES RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
TABLE 137. UNITED STATES RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 138. UNITED STATES RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 139. UNITED STATES RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY IL INHIBITORS, 2018-2024 (USD MILLION)
TABLE 140. UNITED STATES RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY IL INHIBITORS, 2025-2030 (USD MILLION)
TABLE 141. UNITED STATES RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY SMALL MOLECULES, 2018-2024 (USD MILLION)
TABLE 142. UNITED STATES RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY SMALL MOLECULES, 2025-2030 (USD MILLION)
TABLE 143. UNITED STATES RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 144. UNITED STATES RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 145. UNITED STATES RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY B-CELL DEPLETING AGENTS, 2018-2024 (USD MILLION)
TABLE 146. UNITED STATES RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY B-CELL DEPLETING AGENTS, 2025-2030 (USD MILLION)
TABLE 147. UNITED STATES RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY IL INHIBITORS, 2018-2024 (USD MILLION)
TABLE 148. UNITED STATES RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY IL INHIBITORS, 2025-2030 (USD MILLION)
TABLE 149. UNITED STATES RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY JAK INHIBITORS, 2018-2024 (USD MILLION)
TABLE 150. UNITED STATES RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY JAK INHIBITORS, 2025-2030 (USD MILLION)
TABLE 151. UNITED STATES RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 152. UNITED STATES RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 153. UNITED STATES RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 154. UNITED STATES RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 155. UNITED STATES RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 156. UNITED STATES RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 157. UNITED STATES RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 158. UNITED STATES RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 159. CANADA RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
TABLE 160. CANADA RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2030 (USD MILLION)
TABLE 161. CANADA RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
TABLE 162. CANADA RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
TABLE 163. CANADA RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 164. CANADA RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 165. CANADA RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY IL INHIBITORS, 2018-2024 (USD MILLION)
TABLE 166. CANADA RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY IL INHIBITORS, 2025-2030 (USD MILLION)
TABLE 167. CANADA RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY SMALL MOLECULES, 2018-2024 (USD MILLION)
TABLE 168. CANADA RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY SMALL MOLECULES, 2025-2030 (USD MILLION)
TABLE 169. CANADA RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 170. CANADA RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 171. CANADA RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY B-CELL DEPLETING AGENTS, 2018-2024 (USD MILLION)
TABLE 172. CANADA RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY B-CELL DEPLETING AGENTS, 2025-2030 (USD MILLION)
TABLE 173. CANADA RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY IL INHIBITORS, 2018-2024 (USD MILLION)
TABLE 174. CANADA RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY IL INHIBITORS, 2025-2030 (USD MILLION)
TABLE 175. CANADA RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY JAK INHIBITORS, 2018-2024 (USD MILLION)
TABLE 176. CANADA RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY JAK INHIBITORS, 2025-2030 (USD MILLION)
TABLE 177. CANADA RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 178. CANADA RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 179. CANADA RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 180. CANADA RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 181. CANADA RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 182. CANADA RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 183. MEXICO RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
TABLE 184. MEXICO RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2030 (USD MILLION)
TABLE 185. MEXICO RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
TABLE 186. MEXICO RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
TABLE 187. MEXICO RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 188. MEXICO RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 189. MEXICO RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY IL INHIBITORS, 2018-2024 (USD MILLION)
TABLE 190. MEXICO RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY IL INHIBITORS, 2025-2030 (USD MILLION)
TABLE 191. MEXICO RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY SMALL MOLECULES, 2018-2024 (USD MILLION)
TABLE 192. MEXICO RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY SMALL MOLECULES, 2025-2030 (USD MILLION)
TABLE 193. MEXICO RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 194. MEXICO RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 195. MEXICO RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY B-CELL DEPLETING AGENTS, 2018-2024 (USD MILLION)
TABLE 196. MEXICO RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY B-CELL DEPLETING AGENTS, 2025-2030 (USD MILLION)
TABLE 197. MEXICO RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY IL INHIBITORS, 2018-2024 (USD MILLION)
TABLE 198. MEXICO RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY IL INHIBITORS, 2025-2030 (USD MILLION)
TABLE 199. MEXICO RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY JAK INHIBITORS, 2018-2024 (USD MILLION)
TABLE 200. MEXICO RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY JAK INHIBITORS, 2025-2030 (USD MILLION)
TABLE 201. MEXICO RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 202. MEXICO RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 203. MEXICO RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 204. MEXICO RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 205. MEXICO RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 206. MEXICO RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 207. BRAZIL RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
TABLE 208. BRAZIL RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2030 (USD MILLION)
TABLE 209. BRAZIL RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
TABLE 210. BRAZIL RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
TABLE 211. BRAZIL RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 212. BRAZIL RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 213. BRAZIL RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY IL INHIBITORS, 2018-2024 (USD MILLION)
TABLE 214. BRAZIL RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY IL INHIBITORS, 2025-2030 (USD MILLION)
TABLE 215. BRAZIL RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY SMALL MOLECULES, 2018-2024 (USD MILLION)
TABLE 216. BRAZIL RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY SMALL MOLECULES, 2025-2030 (USD MILLION)
TABLE 217. BRAZIL RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 218. BRAZIL RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 219. BRAZIL RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY B-CELL DEPLETING AGENTS, 2018-2024 (USD MILLION)
TABLE 220. BRAZIL RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY B-CELL DEPLETING AGENTS, 2025-2030 (USD MILLION)
TABLE 221. BRAZIL RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY IL INHIBITORS, 2018-2024 (USD MILLION)
TABLE 222. BRAZIL RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY IL INHIBITORS, 2025-2030 (USD MILLION)
TABLE 223. BRAZIL RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY JAK INHIBITORS, 2018-2024 (USD MILLION)
TABLE 224. BRAZIL RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY JAK INHIBITORS, 2025-2030 (USD MILLION)
TABLE 225. BRAZIL RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 226. BRAZIL RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 227. BRAZIL RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 228. BRAZIL RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 229. BRAZIL RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 230. BRAZIL RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 231. ARGENTINA RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
TABLE 232. ARGENTINA RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2030 (USD MILLION)
TABLE 233. ARGENTINA RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
TABLE 234. ARGENTINA RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
TABLE 235. ARGENTINA RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 236. ARGENTINA RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 237. ARGENTINA RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY IL INHIBITORS, 2018-2024 (USD MILLION)
TABLE 238. ARGENTINA RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY IL INHIBITORS, 2025-2030 (USD MILLION)
TABLE 239. ARGENTINA RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY SMALL MOLECULES, 2018-2024 (USD MILLION)
TABLE 240. ARGENTINA RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY SMALL MOLECULES, 2025-2030 (USD MILLION)
TABLE 241. ARGENTINA RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 242. ARGENTINA RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 243. ARGENTINA RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY B-CELL DEPLETING AGENTS, 2018-2024 (USD MILLION)
TABLE 244. ARGENTINA RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY B-CELL DEPLETING AGENTS, 2025-2030 (USD MILLION)
TABLE 245. ARGENTINA RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY IL INHIBITORS, 2018-2024 (USD MILLION)
TABLE 246. ARGENTINA RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY IL INHIBITORS, 2025-2030 (USD MILLION)
TABLE 247. ARGENTINA RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY JAK INHIBITORS, 2018-2024 (USD MILLION)
TABLE 248. ARGENTINA RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY JAK INHIBITORS, 2025-2030 (USD MILLION)
TABLE 249. ARGENTINA RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 250. ARGENTINA RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 251. ARGENTINA RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 252. ARGENTINA RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 253. ARGENTINA RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 254. ARGENTINA RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 255. EUROPE, MIDDLE EAST & AFRICA RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
TABLE 256. EUROPE, MIDDLE EAST & AFRICA RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2030 (USD MILLION)
TABLE 257. EUROPE, MIDDLE EAST & AFRICA RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
TABLE 258. EUROPE, MIDDLE EAST & AFRICA RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
TABLE 259. EUROPE, MIDDLE EAST & AFRICA RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 260. EUROPE, MIDDLE EAST & AFRICA RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 261. EUROPE, MIDDLE EAST & AFRICA RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY IL INHIBITORS, 2018-2024 (USD MILLION)
TABLE 262. EUROPE, MIDDLE EAST & AFRICA RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY IL INHIBITORS, 2025-2030 (USD MILLION)
TABLE 263. EUROPE, MIDDLE EAST & AFRICA RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY SMALL MOLECULES, 2018-2024 (USD MILLION)
TABLE 264. EUROPE, MIDDLE EAST & AFRICA RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY SMALL MOLECULES, 2025-2030 (USD MILLION)
TABLE 265. EUROPE, MIDDLE EAST & AFRICA RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 266. EUROPE, MIDDLE EAST & AFRICA RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 267. EUROPE, MIDDLE EAST & AFRICA RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY B-CELL DEPLETING AGENTS, 2018-2024 (USD MILLION)
TABLE 268. EUROPE, MIDDLE EAST & AFRICA RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY B-CELL DEPLETING AGENTS, 2025-2030 (USD MILLION)
TABLE 269. EUROPE, MIDDLE EAST & AFRICA RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY IL INHIBITORS, 2018-2024 (USD MILLION)
TABLE 270. EUROPE, MIDDLE EAST & AFRICA RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY IL INHIBITORS, 2025-2030 (USD MILLION)
TABLE 271. EUROPE, MIDDLE EAST & AFRICA RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY JAK INHIBITORS, 2018-2024 (USD MILLION)
TABLE 272. EUROPE, MIDDLE EAST & AFRICA RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY JAK INHIBITORS, 2025-2030 (USD MILLION)
TABLE 273. EUROPE, MIDDLE EAST & AFRICA RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 274. EUROPE, MIDDLE EAST & AFRICA RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 275. EUROPE, MIDDLE EAST & AFRICA RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 276. EUROPE, MIDDLE EAST & AFRICA RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 277. EUROPE, MIDDLE EAST & AFRICA RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 278. EUROPE, MIDDLE EAST & AFRICA RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 279. EUROPE, MIDDLE EAST & AFRICA RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 280. EUROPE, MIDDLE EAST & AFRICA RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 281. UNITED KINGDOM RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
TABLE 282. UNITED KINGDOM RARE INFLAMMATORY DISEASE TREATMENT MARKET SIZE, BY THE

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Rare Inflammatory Disease Treatment market report include:
  • F. Hoffmann-La Roche AG
  • Novartis AG
  • Johnson & Johnson
  • Sanofi S.A.
  • Pfizer Inc.
  • AbbVie Inc.
  • Takeda Pharmaceutical Company Limited
  • AstraZeneca PLC
  • Amgen Inc.
  • Bristol-Myers Squibb Company

Related Reports

Rare Autoinflammatory Diseases Drug Market by Indication, Drug Class, Route of Administration, Distribution Channel, End User - Global Forecast 2025-2030 - Product Image

Rare Autoinflammatory Diseases Drug Market by Indication, Drug Class, Route of Administration, Distribution Channel, End User - Global Forecast 2025-2030

  • Report
  • 195 Pages
  • Global
From
Rare Inflammatory Disease Treatment Market Report 2025 - Product Image

Rare Inflammatory Disease Treatment Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Autoimmune Disease Drugs Market by Drug Class (Biologics, Biosimilars, Small Molecules), Mechanism Of Action (B Cell Depleting Agents, Il Inhibitors, Jak Inhibitors), Route Of Administration, Indication, Distribution Channel, End User - Global Forecast 2025-2030 - Product Image

Autoimmune Disease Drugs Market by Drug Class (Biologics, Biosimilars, Small Molecules), Mechanism Of Action (B Cell Depleting Agents, Il Inhibitors, Jak Inhibitors), Route Of Administration, Indication, Distribution Channel, End User - Global Forecast 2025-2030

  • Report
  • 188 Pages
  • Global
From
Adult-onset Still Disease Market: Focus on Regional and Country Analysis - Analysis and Forecast, 2025-2035 - Product Image

Adult-onset Still Disease Market: Focus on Regional and Country Analysis - Analysis and Forecast, 2025-2035

  • Report
  • Global
From
Periodic Fever Syndrome - Global Strategic Business Report - Product Image

Periodic Fever Syndrome - Global Strategic Business Report

  • Report
  • 390 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.